Abbisko Therapeutics Co. Ltd. has synthesized new GTPase KRAS G12V and G12D mutant inhibitors designed for use in the treatment of cancer.

Tyk Medicines Inc. has identified N-acetyl-β-D-glucosaminidase (O-GlcNAcase; OGA) inhibitors described as potentially useful for the treatment of cancer, metabolic diseases, Alzheimer’s disease and progressive supranuclear palsy.

Researchers from the Institut National De La Sante Et De La Recherche Medicale, Universite de Bordeaux and Universite de Paris Cite have reported indane 1,3-dione derivatives acting as furin (PACE; PCSK3) inhibitors potentially useful for the treatment of cancer.

Chengdu Brilliant Pharmaceutical Co. Ltd. and Chengdu Xinke Pharmaceutical Co. Ltd. have disclosed drug conjugates comprising a bone-targeting moiety covalently bound to a radiolabeled-chelating agent through a linker acting as positron emission tomography (PET)/single-photon emission computerized tomography (SPECT) imaging agents. They are reported to be useful for diagnosis and treatment of bone disorders.

Shanghai Simcere Pharmaceutical R&D Co. Ltd. has discovered CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Effective targeted therapies against aggressive breast cancer subtypes, such as triple-negative breast cancer (TNBC), are still lacking. Developing therapeutics targeting nonenzymatic, intracellular proteins with causal roles in TNBC progression remains a significant challenge.

DNA polymerase θ (POLθ) is a specialized, error-prone DNA polymerase that promotes the repair of DNA double-strand breaks through theta-mediated end joining (TMEJ), an alternative pathway that operates independently of homologous recombination.

Kinoteck Therapeutics Co. Ltd. has discovered nitrogen-containing heterocyclic derivatives acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the treatment of cancer.